It promotes gradual weight loss, which is safer and more sustainable compared to rapid weight loss methods
Active cancer or history of certain cancers is a contraindication for growth hormone secretagogues (CJC-1295, ipamorelin, tesamorelin, sermorelin), as elevated GH and IGF-1 can promote tumor growth
Dual GLP1 and GIP agonists Tirzepatide is a once weekly, subcutaneous, unimolecular dual RA (GLP-1 and GIP) which has comparable GIP receptor binding affinity to native GIP and 5 times lower GLP-1 receptor affinity than that of native GLP-1
Although it is present in any type cell, its absolute deficiency is incompatible with life
Initially, clinicians prescribed these medications primarily for glycemic control in patients with type 2 diabetes